Urological and Genital Diseases: Chronic kidney disease (CKD) Surgery Chronic kidney disease (CKD)
Conditions
Interventions
Double blind placebo controlled study of individuals with mild-to-moderate CKD. Subjects receive both Slow Sodium tablets (equivalent to 150 mmol/9 grams per day) and placebo tablets, with each admini
Sponsors
Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Eligibility
Inclusion criteria
Inclusion criteria: 1. Chronic kidney disease (as defined by calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by Cockcroft-Gault formula) 2. 18-75 years old
Exclusion criteria
Exclusion criteria: 1. 75 years old 2. 3g/24hours of proteinuria 3. Calculated creatinine clearance160 mmHg, diastolic BP>100 mmHg on/off anti hypertensive medication) 5. Diabetes mellitus 6. Tobacco smoking 7. Total fasting cholesterol .6 mmol/L 8. Uncontrolled heart failure OR active IHD (MI in last 3 months or current angina) 9. Chronic liver failure 10. Active malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Essentially the 'outcome measure' is as detailed in the hypothesis above i.e. that on the high sodium part of the study (when receiving Slow Sodium tablets), participants will have increased levels of circulating (plasma) ADMA, increased urinary ADMA and reduced urinary DMA . It is also hoped that this will be paralleled by appropriate changes in endothelial function (ie that endothelium dependent forearm blood flow will occur in parallel with changes in ADMA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed